All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2021
Details:
The percentage of hospitalization, admission to ICU, mechanical ventilation requirement and death was 1.7% vs. 17.1%, 0% vs. 8.6%, 0% vs. 5.7% and 0%, vs. 2.9% in Proxalutamide and placebo arms respectively.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2021
Details:
According to the latest data from the trial, the percentage of hospitalisation, ICU admission, and the need for mechanical ventilation and death was at 1.7% versus 17.1%, 0% versus 8.6%, 0% versus 5.7% and 0% versus 2.9% in the Proxalutamide and placebo cohorts, respectively.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Proxalutamide
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Proxalutamide is a new androgen receptor (AR) antagonist developed in by Kintor Pharmaceutical and is currently undergoing phase I-III clinical trials in China and the US for the treatment of prostate cancer and breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Kangtai’s candidate is among more than 10 potential vaccines Chinese scientists have brought into various phases of clinical trials in efforts to counter the virus that has killed more than 1.1 million people globally.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-1387,Entecavir
Therapeutic Area: Infections and Infectious Diseases Product Name: APG-1387
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Findings from the preclinical study show that APG-1387 is able to clear chronic HBV infection in various mouse models with a unique induction of apoptosis and immunoregulation mechanism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Envafolimab
Therapeutic Area: Infections and Infectious Diseases Product Name: ASC22
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
ASC22(Envafolimab) Phase IIa clinical trial is a single dose escalation study with three subcutaneously administered doses (0.3, 1.0 and 2.5 mg/kg) to explore the safety and efficacy of ASC22(Envafolimab) in chronic hepatitis B patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Ad5-nCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
The randomized, double-blind, placebo-controlled, Phase II trial of the vaccine was conducted in Wuhan, China for more than 500 healthy adults aged 18 years or older.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APG-1387,Entecavir
Therapeutic Area: Infections and Infectious Diseases Product Name: APG-1387
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
The global multi-center, open-label Phase II study is designed to evaluate the safety and efficacy of APG-1387 in combination with entecavir in patients with CHB who are treatment-naive or -experienced.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Advantech Capital
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 22, 2020
Details:
The Funding will provide the Company with the necessary resources to continue its development of an inactivated vaccine against COVID-19 named CoronaVac.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2020
Details:
96 persons in three age groups have received the vaccine in the first phase of clinical trial as of April 23. The vaccine has shown good safety so far and vaccine receivers are still under observation.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
